MISSION & VALUES
Graftys was incepted in 2005 by three business-driven executives of the orthopedic industry and an academic Research Director in the field of synthetic biomaterials, leading a renowned Research Unit in Nantes. The Company is headed by Gilles Alberici, CEO and Chairman of the Board, a seasoned pharma and biotech entrepreneur.
Graftys has implemented a hybrid business model combining a worldwide commercial activity and a strong R&D platform in liaison with the French Academic Research.
Graftys’ mission is to become a major player in the design, manufacturing and commercialization of synthetic bone biomaterials.
To achieve that goal, Graftys has developed an innovation-driven growing pipeline through partnerships with leading academic research institutions in Europe and has progressively built a portfolio aimed at addressing specific and unmet patients’ medical needs. Graftys commercializes its first generation of products in more than 25 countries, including the United States.
PharmD, PhD, acting CEO
Founder & Deputy CEO
Founder & VP Business Development
Founder & acting CSO
Founder & Consultant
Alain then served as a strategy consultant for several small- and medium- sized companies. In 1994, he joined Zimmer Inc., where he was appointed CEO in France and was promoted to VP Europe in 1997.
In 2001, he was back to consultancy for orthopedic firms before creating Graftys in 2005.
GOVERNANCE & INVESTORS
• Gilles Alberici, Chairman
• Alain Tornier, private investor and entrepreneur in medtech
• Aurélien Valet
• Alain Valet
• Philippe Dubrou, private investor and entrepreneur
• Bruno Paglia, ACG Group
• OREO finance
• ACG management
• Financière Mirabel
• Graft’Invest holding (minority investors, employees, love money)